{"schema_version":"secwatch.filing_event.v1","accession":"0000805928-22-000100","form_type":"8-K","ticker":"AXGN","cik":"0000805928","company_name":"Axogen, Inc.","filed_at":"2022-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:58.187836+00:00","generated_at":"2026-06-24T05:33:09.000741+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Axogen Q2 revenue $34.5M (+3% YoY); adjusted net loss narrows to $2.6M; reaffirms FY2022 guidance","bullets":["Net revenue $34.5M, +3% YoY; ex-Avive (suspended June 2021) revenue grew 9%.","Gross margin 81.8% vs 78.9% in Q2 2021 (included $1.4M Avive write-down).","Adjusted net loss $2.6M ($0.06/share) vs loss $3.7M ($0.09/share) in Q2 2021.","Cash+investments $64.3M, down from $73.7M at March 2022; $3.9M capex for Dayton facility.","FY2022 revenue guidance reaffirmed at $135-142M; gross margin expected above 80%."],"urls":{"canonical":"https://secwatch.observer/filing/0000805928-22-000100","json":"https://secwatch.observer/filing/0000805928-22-000100.json","markdown":"https://secwatch.observer/filing/0000805928-22-000100.md","text":"https://secwatch.observer/filing/0000805928-22-000100.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/805928/000080592822000100/0000805928-22-000100-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/805928/000080592822000100/axgn-20220803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T05:33:09.000741+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}